Determining the minimum clinically important differences for outcomes in the DOMINO trial.
about
Omega-3 fatty acids for the treatment of dementiaRivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseMethods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) systematic reviewThe effectiveness and safety of acupuncture for patients with Alzheimer disease: a systematic review and meta-analysis of randomized controlled trialsOptimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trialEfficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trialLack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial.The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis planDisease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver OutcomesAdd-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations.Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled studyClinical significance in dementia research: a review of the literature.Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial.Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementiasRole of citalopram in the treatment of agitation in Alzheimer's disease.Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regressionEtanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trialOutcome measures for Parkinson's disease dementia: a systematic review.Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response.Pharmacotherapies for sleep disturbances in dementia.Citalopram Ameliorates Impairments in Spatial Memory and Synaptic Plasticity in Female 3xTgAD MiceCost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).Acupuncture plus Herbal Medicine for Alzheimer's Disease: A Systematic Review and Meta-Analysis.The Use of Intercessory Prayer to Reduce Disruptive Behaviors of Patients With Dementia: A Pilot Feasibility Study.Determination of the minimal clinically important difference on the Australian therapy outcome measures for occupational therapy (AusTOMs-OT).Efficacy and Safety of Auricular Acupuncture for Cognitive Impairment and Dementia: A Systematic Review.
P2860
Q24185910-7674EC15-4EAE-492D-98DF-018CEC596124Q24186551-41D64AC6-D7D0-4553-A457-9076AD057D15Q24187067-3F8A71C3-BDE9-40E8-9DAB-9AB17C410EF2Q26824003-8AD1B575-8D1D-4D7A-8C91-1DF0D3EC7155Q27007532-D45DB178-709B-406D-82F1-51B5F47B940EQ28728380-8B85150F-182F-47F4-9340-28F251F4C959Q28730154-2CB5C1F9-DFBC-400F-B4F8-7E9F42896A38Q31163645-CBF797F0-8DE3-431F-B7A0-96D40B5AB5E6Q33589655-C60BEB39-9B22-41E9-8739-ABD1B322AEFCQ33721964-77752A00-3F59-43D1-938B-3F7080442FCDQ33781824-098639BC-0554-4C98-AB25-68AD9FF9E178Q33800161-E9547703-113E-4F5C-AE03-27C28B9EAFC4Q33852962-5B3AB39F-B610-4C01-A636-2812F68F68B6Q33863623-81D3A57C-9B25-4D4F-8242-EE7AF79C4D8FQ34135756-609512E6-FFE4-4443-B739-629CE2983206Q34404220-10F6D29E-27BA-4D1F-9355-EFA56E68650FQ34485968-783D18EC-E657-48BE-BBF3-2DF23B153200Q34528182-A8BB31D3-DD5A-401A-B6C4-B1DA5AF22FE2Q34675960-846868F8-4B32-4EE6-8F23-A7726747F90FQ35332241-F148A33C-7CF6-496A-AA2E-9A4982738887Q35671005-818502A8-59B2-428A-B460-9D53781B8461Q36688859-453F6ECF-8E5D-4A42-810D-BFBE27656E0DQ38150922-0F19C763-870A-436E-8CF0-9F1FCD25D9CFQ39010202-85AAC3B5-1524-47A0-9C10-E1009F97BC4FQ42556970-BA8675C1-C432-44C6-BAA9-DF8E06834DA3Q47163824-33789ACA-7BCC-4396-9D8D-771ACD8148BAQ47619319-67B46060-A565-483D-B849-AF98BF1BA931Q48037369-B411CE37-0396-4A1E-B765-14150D87B6B5Q48067560-75296AA4-8A99-4A68-AF28-5599832D1310Q55438702-361F49E0-CE11-405F-94BD-9B4A08FD6191
P2860
Determining the minimum clinically important differences for outcomes in the DOMINO trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Determining the minimum clinic ...... outcomes in the DOMINO trial.
@en
Determining the minimum clinic ...... outcomes in the DOMINO trial.
@nl
type
label
Determining the minimum clinic ...... outcomes in the DOMINO trial.
@en
Determining the minimum clinic ...... outcomes in the DOMINO trial.
@nl
prefLabel
Determining the minimum clinic ...... outcomes in the DOMINO trial.
@en
Determining the minimum clinic ...... outcomes in the DOMINO trial.
@nl
P2093
P2860
P50
P356
P1476
Determining the minimum clinically important differences for outcomes in the DOMINO trial
@en
P2093
Ajay Macharouthu
Alan Hughes
Ashley Baldwin
Bart Sheehan
Clive Holmes
Craig Ritchie
David Findlay
James Lindesay
Jessica Adams
Mary Griffin
P2860
P304
P356
10.1002/GPS.2607
P407
P50
P577
2010-09-16T00:00:00Z